about
Stem cell therapy for diabetes mellitusC-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitusRecombinant anti-P protein autoantibodies isolated from a human autoimmune library: reactivity, specificity and epitope recognition.Metabolic and pancreatic effects of bone marrow mesenchymal stem cells transplantation in mice fed high-fat diet.Therapeutic efficacy and biodistribution of allogeneic mesenchymal stem cells delivered by intrasplenic and intrapancreatic routes in streptozotocin-induced diabetic mice.A Methodology for the Development of RESTful Semantic Web Services for Gene Expression AnalysisCultured Human Adipose Tissue Pericytes and Mesenchymal Stromal Cells Display a Very Similar Gene Expression Profile.Cytokine profile and lymphocyte subsets in type 2 diabetesTranscriptional profiling reveals intrinsic mRNA alterations in multipotent mesenchymal stromal cells isolated from bone marrow of newly-diagnosed type 1 diabetes patientsXenogeneic Mesenchymal Stromal Cells Improve Wound Healing and Modulate the Immune Response in an Extensive Burn Model.Plasma eicosanoid profiles determined by high-performance liquid chromatography coupled with tandem mass spectrometry in stimulated peripheral blood from healthy individuals and sickle cell anemia patients in treatment.Multipotent mesenchymal stromal cells from patients with newly diagnosed type 1 diabetes mellitus exhibit preserved in vitro and in vivo immunomodulatory properties.Immunological Balance Is Associated with Clinical Outcome after Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes.Caspase-mediated cleavage of the exosome subunit PM/Scl-75 during apoptosisDynamic changes of the Th17/Tc17 and regulatory T cell populations interfere in the experimental autoimmune diabetes pathogenesis.Microvascular Complications in Type 1 Diabetes: A Comparative Analysis of Patients Treated with Autologous Nonmyeloablative Hematopoietic Stem-Cell Transplantation and Conventional Medical Therapy.Autologous haematopoietic stem cell transplantation reduces abnormalities in the expression of immune genes in multiple sclerosis.Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation.Defective expression of apoptosis-related molecules in multiple sclerosis patients is normalized early after autologous haematopoietic stem cell transplantation.Homeostatic proliferation leads to telomere attrition and increased PD-1 expression after autologous hematopoietic SCT for systemic sclerosis.Up-regulation of fas and fasL pro-apoptotic genes expression in type 1 diabetes patients after autologous haematopoietic stem cell transplantationImmune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patientsMast cells control insulitis and increase Treg cells to confer protection against STZ-induced type 1 diabetes in miceHaematopoietic stem cell transplantation for refractory Takayasu's arteritisEmerging CAR T cell therapies: clinical landscape and patent technological routesEmerging Role of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Pathogenesis of Haematological Malignancies
P50
Q27011453-38294007-D0A8-4127-928F-4ED3ECC36BC1Q28241260-658CB309-5C63-435C-B373-B8F735A9944DQ30926307-7C6E988B-D338-4763-8992-58DA705F3761Q35552255-456DFFF7-4F51-42A8-BF6A-053DECB58944Q35609423-1A4CA192-DF3C-477A-AE00-0E04E39DB320Q35710705-146AFB4C-61AD-4A26-922A-BB3FB2FB724DQ36301649-AB4465A3-3168-41DC-9D36-A997E2F2DA3AQ36761265-03D9C699-91F7-4A2D-A421-CBF5115302F7Q37089931-5043A70B-7411-40BC-BF2F-BFBA49782198Q39009452-8E6B845D-D658-475D-BCA0-772DD34756DEQ40758763-A5749134-C58B-430E-B3CF-7F970427D831Q41196008-B626EBD8-0329-4C99-AA82-B6DBD9F7CDFFQ42320502-8CA97329-EE86-4FE2-820D-AD4D56FD061DQ42836117-9DB770F4-926C-49AE-B2F5-BE0CF99E4469Q43855229-F3994A5D-D539-4420-A420-6E6A2201296FQ47157807-DB61F2EC-4404-4F3A-A896-919B2C999B40Q48608172-2A6EA0BE-0B3D-42E4-B8C1-139CDE0D21A8Q50641737-619E8B9B-43EA-4EFE-BB9F-4A52FB517166Q51240973-15E60B69-40F8-4E7B-9DB8-354C4688F5EDQ52718442-F3AEEA73-0FE3-43F9-AFBF-0EF0EDD3BD1AQ56787009-6E2EB986-9BBE-4138-83B9-D076EAFB08D5Q56893060-A4BC56F1-681B-4979-AD48-C5BBCF2B02A0Q58855536-06A33E5A-3432-44BE-9564-E9C273CAE9E7Q58855547-8521E709-3A75-41A3-8231-C2B53FCD72F8Q91186129-4EDDC3C0-65A8-4FD6-A8A0-32D5B6A994F4Q91688736-5D6B86E7-D918-4088-9C5E-0580F2135FBC
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Kelen Cristina Ribeiro Malmegrim
@ast
Kelen Cristina Ribeiro Malmegrim
@en
Kelen Cristina Ribeiro Malmegrim
@es
Kelen Cristina Ribeiro Malmegrim
@nl
type
label
Kelen Cristina Ribeiro Malmegrim
@ast
Kelen Cristina Ribeiro Malmegrim
@en
Kelen Cristina Ribeiro Malmegrim
@es
Kelen Cristina Ribeiro Malmegrim
@nl
prefLabel
Kelen Cristina Ribeiro Malmegrim
@ast
Kelen Cristina Ribeiro Malmegrim
@en
Kelen Cristina Ribeiro Malmegrim
@es
Kelen Cristina Ribeiro Malmegrim
@nl
P1053
H-1016-2015
P106
P1153
6506686278
P21
P2798
P31
P3829
P496
0000-0002-9303-0086